EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 39 / No 2 (June 2007) J Extra Corpor Technol, 39 2 (2007) 81-86 References
Free Access
Issue
J Extra Corpor Technol
Volume 39, Number 2, June 2007
Page(s) 81 - 86
DOI https://doi.org/10.1051/ject/200739081
Published online 15 June 2007
  1. Linden MD. The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombolysis. 2003;16:129–47. [CrossRef] [PubMed] [Google Scholar]
  2. Jones K, Nasrallah F, Darling E, Clay N, Searles B. The in vitro effects of aprotinin on twelve different ACT tests. J Extra Corpor Technol. 2004;36:51–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Swartz MF, Fink GW, Searles B. Aprotinin and hemostasis monitoring concerns during cardiac surgery. J Extra Corpor Technol. 2004;36:375–83. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108:1076–82. [CrossRef] [Google Scholar]
  5. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg. 1996;112:154–61. [CrossRef] [Google Scholar]
  6. Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg. 1997;113:611–3. [CrossRef] [Google Scholar]
  7. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003;18:269–76. [CrossRef] [PubMed] [Google Scholar]
  8. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res. 1976;8:413–6. [CrossRef] [Google Scholar]
  9. Yin ET, Wessler S, Butler J. Plasma heparin: A unique, practical, submicrogram-sensitive assay. J Lab Clin Med. 1973;81:298–310. [Google Scholar]
  10. Yin ET. Method and compositions for heparin assays. US Patent 4,946,775. [Google Scholar]
  11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10. [CrossRef] [Google Scholar]
  12. Bevan DH. Cardiac bypass haemostasis: Putting blood through the mill. Br J Haematol. 1999;104:208–19. [CrossRef] [Google Scholar]
  13. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 1981;193:105–11. [CrossRef] [PubMed] [Google Scholar]
  14. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;108:1076–82. [CrossRef] [Google Scholar]
  15. Hendrice C, Schmartz D, Pradier O. Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 1995;9:245–9. [CrossRef] [Google Scholar]
  16. Gravlee GP, Brauer SD, Roy R, et al. Predicting the pharmacodynamics of heparin: a clinical evaluation of the Hepcon system 4. J Cardiothorac Anesth. 1987;1:379–87. [CrossRef] [Google Scholar]
  17. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:518–27. [CrossRef] [Google Scholar]
  18. Hansen R, Koster A, Kukucka M, Mertzlufft F, Kuppe H. A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: A pilot investigation. Anesth Analg. 2000;91:533–8. [CrossRef] [PubMed] [Google Scholar]
  19. Beholz S, Grubitzsch H, Bergmann B, Wollert HG, Eckel L. Hemostasis management by use of Hepcon/HMS™: Increased bleeding without increased need for blood transfusion. Thorac Cardiovasc Surg. 1999;47:322–7. [CrossRef] [PubMed] [Google Scholar]
  20. Gray E, Walker AD, Mulloy B, Barrowcliffe TW. A collaborative study to establish the 5th International standard for unfractionated heparin. Thromb Haemost. 2000;84:1017–22. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.